Premium
Prevention and treatment of Lewis rat experimental allergic encephalomyelitis with a monoclonal antibody to the T cell receptor Vβ8.2 segment
Author(s) -
Imrich Horst,
Kugler Christine,
TorresNagel Nora,
Dörries Rüdiger,
Hünig Thomas
Publication year - 1995
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.1830250724
Subject(s) - encephalomyelitis , monoclonal antibody , immunology , myelin basic protein , experimental autoimmune encephalomyelitis , t cell receptor , t cell , receptor , immunization , biology , myelin , monoclonal , microbiology and biotechnology , antibody , multiple sclerosis , immune system , endocrinology , central nervous system , biochemistry
Abstract The predominance of T cell receptor (TCR) Vβ8.2 utilization by encephalitogenic T cells induced in Lewis rats by immunization with myelin basic protein (MBP) is controversial. Thus, both an almost exclusive usage of Vβ8.2 [Burns, F. R., Li, X., Shen, N., Offner, H., Chou, Y. K., Vandenbark, A. A. and Heber‐Katz, E., J. Exp. Med. 1989. 169 : 27; Chluba, J., Steeg, C., Becker, A., Wekerle, H. and Epplen, J. T., Eur. J. Immunol. 1989. 19 : 279] and a quite diverse Vβ composition of CD4 T cells causing experimental autoimmune encephalomyelitis (EAE) [Sun, D., Gold, P. D., Smith, L., Brostoff, S. and Coleclough, C., Eur. J. Immunol. 1992. 22 : 591; Sun, D., Le, J. and Coleclough, C., Eur. J. Immunol. 1993. 23 : 494] have been reported. Using a recently developed monoclonal antibody (mAb) specific for TCR Vβ8.2, we show that postnatal treatment effectively eliminates Vβ8.2‐bearing cells and prevents MBP‐induced EAE in the majority of Lewis rats. Moreover, treatment of adult Lewis rats with Vβ8.2‐specific mAb as late as on day 12 after MBP immunization suppressed the development of neurological symptoms. Thus, Vβ8.2‐bearing cells do play a decisive role in Lewis rat EAE, and suppression of the small (5%) Vβ8.2‐expressing T cell subset provides an effective therapeutic strategy.